News

How a cancer diagnosis affects income


 

Cancer patient
receiving treatment
Photo by Rhoda Baer

A new study indicates that when American adults are diagnosed with

cancer, they experience significant decreases in the probability of

working, in the number of hours they work, and correspondingly, in their

incomes.

Additionally, these effects appear to be more pronounced among men than women.

Anna Zajacova, PhD, of the University of Wyoming in Laramie, and her colleagues reported these findings in Cancer.

The researchers analyzed data from the Panel Study of Income Dynamics, a nationally representative, prospective, population-based, observational study with individual and family level economic information. The data spanned the period from 1999 to 2009.

The team used models to estimate the impact of cancer on employment, hours worked, individual income, and total family income.

The results showed that, after a cancer diagnosis, the probability of a patient being employed dropped by almost 10 percentage points, and hours worked declined by up to 200 hours, or about 5 weeks of full-time work, in the first year.

Annual labor market earnings dropped almost 40% within 2 years of diagnosis, and they remained lower than before diagnosis. Total family income declined by 20%, although it recovered within 4 years of cancer diagnosis.

These effects were primarily driven by losses among male cancer survivors. For women diagnosed with cancer, the losses were largely not statistically significant.

“Fifteen million American adults are cancer survivors, and American families need economic support while they are dealing with the rigors of cancer treatment,” Dr Zajacova said.

“Our paper suggests that families where an adult—especially a working-age male—is diagnosed with cancer suffer short-term and long-term declines in their economic well-being. We need to improve workplace and insurance safety nets so families can focus on dealing with the cancer treatment rather than deal with the financial and employment fallout.”

Recommended Reading

Emerging evidence is resolving questions in CML management
MDedge Hematology and Oncology
NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
MDedge Hematology and Oncology
Novel compound could treat leukemia
MDedge Hematology and Oncology
Antibody can turn AML cells against each other
MDedge Hematology and Oncology
Model recapitulates cancer susceptibility in DBA
MDedge Hematology and Oncology
Study provides clearer picture of JMML
MDedge Hematology and Oncology
Drug granted breakthrough designation for ALL
MDedge Hematology and Oncology
6PGD inhibitors could treat leukemia, other cancers
MDedge Hematology and Oncology
NCCN creates tool to aid treatment decisions
MDedge Hematology and Oncology
Study reveals potential drivers of CLL
MDedge Hematology and Oncology